Quick Answer
Raphael Pharmaceutical Inc. reported Research And Development Expense of $631.0 thousand for the year ending 2025.
- Raphael Pharmaceutical Inc. showed a decrease of -18.7% in Research And Development Expense from 2024 to 2025.
- This data is from Raphael Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $69.0 thousand | Q1 2021: $169.0 thousand | Q2 2021: $222.0 thousand | Q3 2021: $161.0 thousand | Q1 2022: $86.0 thousand | Q2 2022: $84.0 thousand | Q3 2022: $332.0 thousand | Q1 2023: $114.0 thousand | Q2 2023: $293.0 thousand | Q3 2023: $510.0 thousand | Q1 2024: $379.0 thousand | Q2 2024: $24.0 thousand | Q3 2024: $162.0 thousand | Q1 2025: $72.0 thousand | Q2 2025: $141.0 thousand | Q3 2025: $73.0 thousand.
- Over the full 6 years of available data (2020 to 2025), Raphael Pharmaceutical Inc.'s Research And Development Expense has grown by 36.9%.
- Historical annual values: Fiscal year 2025: $631.0 thousand | Fiscal year 2024: $776.0 thousand | Fiscal year 2023: $569.0 thousand | Fiscal year 2022: $1.18 million | Fiscal year 2021: $776.0 thousand | Fiscal year 2020: $461.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: